title: Prognostic value of connexin43 expression in patients with clinically localized prostate cancer.
abstract: Connexins (Cxs) are a family of transmembrane proteins that build cell-to-cell channels in gap junctions. Gap junctions composed of Cxs have an essential role in intercellular communication, adhesion and cell differentiation. Several studies investigated the role of connexin43 (Cx43) in different carcinomas; however, none investigated its prognostic role in prostate cancer. Cx43 expression and relationship with established prognostic features were assessed in a cohort of 102 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. Cx43 expression in prostate cancer was significantly associated with established features indicative of worse prognosis, such as follow-up time (P < 0.001) and preoperative PSA (P < 0.007). Patients with lower Cx43 expressions in tumours have shorter follow-up time, which indicated shorter disease-free survival and higher preoperative PSA values. Furthermore, tumours with positive surgical margins (P < 0.001) showed significantly lower Cx43 expression compared with tumours without this feature. In univariate (P < 0.001) and multivariate (P = 0.014) analyses, decreased Cx43 expression was found to be a significant predictor of biochemical recurrence free-survival. Study results show the association of decreased Cx43 expression with prostate cancer progression. Moreover, Cx43 could serve as an additional prognostic marker and used together with traditional prognostic markers might help in further stratifying the risk of disease progression in patients with prostate cancer.
authors.affiliation: Department of Urology, Varaždin General Hospital, Varaždin, Croatia.
authors.forename: G
authors.initials: G
authors.lastname: Benko
authors.forename: B
authors.initials: B
authors.lastname: Spajić
authors.forename: A
authors.initials: A
authors.lastname: Demirović
authors.forename: G
authors.initials: G
authors.lastname: Stimac
authors.forename: B
authors.initials: B
authors.lastname: Kru Sbreve Lin
authors.forename: D
authors.initials: D
authors.lastname: Tomas
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018031:Connexin 43 / Q000378:metabolism*; D018450:Disease Progression; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D018031:Connexin 43; D017430:Prostate-Specific Antigen